Press Releases

NEWS

Our science is making news.
Stay in touch.

Follow us on LinkedIn.

Press Releases

Ymmunobio Accepted into Innosuisse Core Coaching

Mar 8

Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board

Mar 2

FDA Grants Orphan Drug Designation to Ymmunobio’s CEACAM Antibody for the Treatment of Liver Cancer

Feb 28

In the News

Drug Discovery & Development

Jan 31

Fierce Biotech: Appointment of Michel Janicot

Jan 13

BioPharma Dive

Jun 14, 2022

SEE MORE NEWS

Mar 8

Ymmunobio Accepted into Innosuisse Core Coaching

Participation in the international program guides startups in creating and developing business traction RIEHEN, SWITZERLAND, March 8,...

Mar 2

Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory Board

Mitsuro Kanda, MD, PhD, and Vishal Khairnar, PhD, join growing biotech company developing antibodies as therapies against various cancers...

Feb 28

FDA Grants Orphan Drug Designation to Ymmunobio’s CEACAM Antibody for the Treatment of Liver Cancer

Ymmunobio developed CEACAM antibody YB-200 for the treatment of hepatocellular carcinoma (HCC) RIEHEN, SWITZERLAND, February 28, 2023 ─...

Feb 16

Ymmunobio Appoints Dr. Caroline Germa to Board of Directors

Medical oncologist & CMO at Transcenta joins the board of growing biotech company February 16, 2023 ─ Ymmunobio, a preclinical stage...

Feb 8

Ymmunobio Appoints Angela S. Gibbs as Chief Business Officer

Growing preclinical-stage biotech company adds to executive team RIEHEN, SWITZERLAND, February 8, 2023 ─ Ymmunobio AG, a preclinical...

Jan 31

Ymmunobio Signs Transfer Ownership Agreement with Nagoya University for NPTXR antibodies

Research indicates that NPTXR may have utility for treatment of gastro-intestinal cancers. Read more here: https://www.prnewswire.com/new...

Jan 10

Ymmunobio Appoints Dr. Michel Janicot as Chief Development Officer

Ymmunobio adds to executive team. Read more here: https://www.biopharmadive.com/press-release/20230109-ymmunobio-appoints-dr-michel-janic...

Oct 19, 2022

Ymmunobio selected by BIO-Europe to participate in its Start-up Spotlight Session

RIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM...

Oct 13, 2022

Ymmunobio to Present Pre-Clinical Data at Annual Meeting of the Society for Immunotherapy of Cancer

Ymmunobio to Present Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200 at the 37th Annual Meeting of the Society for...

Jun 14, 2022

Ymmunobio Signs Collaboration Agreement with YUMAB

RIEHEN, Switzerland — Ymmunobio to optimize its antibody development with YUMAB’s antibody technology Ymmunobio AG, a preclinical stage...

Apr 5, 2022

Ymmunobio AG Signs Patent Purchase Agreement with LeukoCom GmbH

Agreement expands the company strategy to employ the immune system in the development of cancer therapies RIEHEN, SWITZERLAND, April 7,...

Jan 19, 2022

Ymmunobio AG announces appointment of Dr. Keith Skubitz

Dr. Skubitz, Professor for Hematology & Oncology, University of Minnesota, joins Ymmunobio as scientific advisor for development of...

NEWS

Our science is making news.
Stay in touch.

Follow us on LinkedIn.

Join our mailing list

Press Releases

READ MORE

In the News

SEE MORE NEWS

Archive

We will be in touch soon.

NEWS

Our science is making news. Stay in touch. Follow us on LinkedIn.

Join our mailing list

Press Releases

READ MORE

In the News

SEE MORE NEWS

Archive

We will be in touch soon.

Our science is making news.
Stay in touch.

Follow us on LinkedIn.